ClinicalTrials.gg
CompletedNCT05182840Updated Oct 22, 2024Results posted

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

A Phase 2 interventional study of BI 690517 and Placebo to BI 690517 in Kidney Disease, Chronic, sponsored by Boehringer Ingelheim. Completed at 203 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
714
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Enrollment
4th of 20
714 · median 77
Started
2022
with 3 others
Phase 2
4 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
4 of 20
Boehringer Ingelheim

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 2, and was the 5th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study.

The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function in people with chronic kidney disease when taken alone or in combination with a medicine called empagliflozin.

In the first part of the study, participants take empagliflozin or placebo as tablets every day for 2 months. Placebo tablets look like empagliflozin tablets but do not contain any medicine.

In the second part, participants are divided into several groups. Depending on the group, the participants then additionally take different doses of BI 690517 or placebo as tablets for 3.5 months. In this case, placebo tablets look like BI 690517 tablets but do not contain any medicine.

Participants are in the study for about 6 months. During this time, they visit the study site about 12 times. Where possible, about 4 of the 12 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call.

Participants collect urine samples at home. These samples are then analysed to assess kidney function. At the end of the trial the results are compared between the different groups. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Kidney Disease, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written in accordance with International Council on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
  • Male or female patients of legal adult age (according to local legislation) and aged ≥ 18 years at time of consent.
  • estimated (eGFR, Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 30 and \< 90 mL/min/1.73 m2 at Visit 1 by central laboratory analysis.
  • Urine Albumin Creatinine Ratio (UACR) ≥ 200 and \< 5,000 mg/g in spot urine (midstream urine sample) by central laboratory analysis at Visit 1.1
  • If the patient is taking any of the following medications they should be on a stable dose for at least 4 weeks prior to visit 1 and until first randomisation prior to run-in with no planned change of the therapy during the trial: anti-hypertensives, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), endothelin receptor antagonists, low dose systemic (e.g. prednisolone ≤10 mg or equivalent).
  • Treatment with a clinically appropriate, stable dose of either Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) (but not both together), for ≥ 4 weeks prior to visit 1 and until first randomisation with no planned change of the therapy during the trial.
  • In the Investigator's opinion, any kind of diagnosed chronic kidney disease (Diagnosis can be reached by standard clinical method, no required). Patients with diabetic kidney disease must have type 2 diabetes mellitus and their treatment (including GLP1 receptor agonist) should be unchanged or changes deemed minor (according to investigator's judgement) within 4 weeks prior to Visit 1 and until first randomisation.
  • (HbA1c) \< 10.0% at Visit 1 measured by the central laboratory.
  • Serum potassium ≤ 4.8 mmol/L at Visit 1 measured by the central laboratory.
  • Seated Systolic Blood Pressure (SBP) ≥ 110 and ≤ 160 mmHg and Diastolic Blood Pressure (DBP) ≥ 65 and ≤ 110 mmHg at Visit 1 (mean values from three Blood Pressure (BP) measurements) and optimised anti-hypertensive treatment according to local standard of care and investigator's judgement.
  • (BMI) ≥ 18.5 and \< 50 kg/m2 at Visit 1.
  • Women of child-bearing potential2 () must be ready and able to use highly effective methods of . Such methods should be used throughout the trial. Men must be vasectomised or willing and able to use a condom if their partner is a WOCBP.

Additional inclusion criteria to be assessed before second randomisation (start of Treatment Period):

  • Serum potassium ≤ 4.8 mmol/L measured by local or central laboratory within 7 days prior to randomisation to the Treatment Period.
  • eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 mL/min/1.73 m2 measured by local or central laboratory within 7 days prior to randomisation to the Treatment Period.

Exclusion criteria

Exclusion criteria

  • Treatment with inhibitors of aldosterone mediated effects (e.g., mineralocorticoid receptor antagonists such as spironolactone), or intake of other potassium sparing diuretics (e.g., amiloride) within 7 days prior to first randomisation or planned during trial treatment phase.
  • Treatment with other Renin Angiotensin Aldosterone System (RAAS) interventions (apart from either Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB)) within 4 weeks prior to Visit 1 and throughout screening or planned during the trial. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial are also excluded.
  • Type 1 diabetes mellitus, or history of other causes of diabetes mellitus (e.g. Latent Autoimmune Diabetes (LADA))
  • Patients at increased risk of ketoacidosis in the opinion of the investigator.
  • Currently receiving Sodium-glucose cotransporter (SGLT)-2 or SGLT-1/2 inhibitor or planned initiation during the trial.

Further criteria apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
714 participants (actual)

Study arms

  • Experimental
    Run-in period: 10 mg empagliflozin

    Drug: Empagliflozin

  • Placebo comparator
    Run-in period: Placebo to empagliflozin 10 mg

    Drug: Placebo to empagliflozin

  • Experimental
    Treatment period: 10 mg empagliflozin + 3 mg BI 690517

    Drug: BI 690517 · Drug: Empagliflozin

  • Experimental
    Treatment period: 10 mg empagliflozin + 10 mg BI 690517

    Drug: BI 690517 · Drug: Empagliflozin

  • Experimental
    Treatment period: 10 mg empagliflozin + 20 mg BI 690517

    Drug: BI 690517 · Drug: Empagliflozin

  • Placebo comparator
    Treatment period: 10 mg empagliflozin + Placebo to BI 690517

    Drug: Placebo to BI 690517 · Drug: Empagliflozin

  • Experimental
    Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517

    Drug: BI 690517 · Drug: Placebo to empagliflozin

  • Experimental
    Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517

    Drug: BI 690517 · Drug: Placebo to empagliflozin

  • Experimental
    Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517

    Drug: BI 690517 · Drug: Placebo to empagliflozin

  • Placebo comparator
    Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517

    Drug: Placebo to BI 690517 · Drug: Placebo to empagliflozin

Interventions

  • Film-coated tablets

    Also known as: Vicadrostat

  • DrugPlacebo to BI 690517

    Film-coated tablets

  • Empagliflozin

  • DrugPlacebo to empagliflozin

    Placebo to empagliflozin

06

What researchers measure

Primary outcomes

  1. Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients

    The adjusted mean change (95% confidence interval) in log transformed FMV UACR from baseline at 14 weeks is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

  2. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients

    Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for all patients is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

  3. Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin

    The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

  4. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin

    Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

  5. Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin

    The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

  6. Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin

    Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

    Time frame: The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.

Secondary outcomes

  1. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation

    Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  2. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder

    Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  3. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)

    Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  4. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis

    Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  5. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation

    Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  6. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder

    Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  7. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)

    Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  8. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis

    Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  9. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation

    Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  10. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder

    Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  11. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward

    Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  12. UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis

    Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  13. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation

    Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 week. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  14. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder

    Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  15. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)

    Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  16. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis

    Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  17. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation

    Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  18. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder

    Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  19. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)

    Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  20. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation

    Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.

  21. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder

    Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  22. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward

    Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.

    Time frame: UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.

  23. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis

    Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

  24. UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis

    Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

    Time frame: At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.

07

Results

Posted Aug 29, 2024

Participant flow

The trial included two randomisations, R1 and R2. At first randomisation R1, patients were 1:1 randomised to a run-in period of 8 weeks and received 10 mg empagliflozin or placebo matching empagliflozin. The run-in period was followed by randomisation R2 at which patients were 1:1:1:1 randomized to a treatment period of 14 weeks to receive one of three doses of BI 690517 or placebo matching BI 690517 in combination with the background medication assigned in the randomized run-in period.

Run-in Period
Participant flow — Run-in Period
MilestoneRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Started35635800000000
Treated with empagliflozin 10 mg or placebo matching empagliflozin 10 mg35635700000000
Completed33233000000000
Not completed242800000000
Withdrew: Not treated0100000000
Withdrew: Other reason but not sponsor termination141800000000
Withdrew: No reason available2200000000
Withdrew: Burden of study procedures2200000000
Withdrew: Change of residence1000000000
Withdrew: Adverse event5500000000
Completed RP and Randomized to TP
Participant flow — Completed RP and Randomized to TP
MilestoneRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Started33233000000000
Completed29828600000000
Not completed344400000000
Withdrew: Did not meet additional inclusion/exclusion criteria for treatment period344400000000
Patients Starting the Treatment Period
Participant flow — Patients Starting the Treatment Period
MilestoneRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Started29828800000000
Did not complete the run-in period and was randomized to treatment period0200000000
Completed run-in period and randomized to treatment period29828600000000
Completed29828800000000
Not completed0000000000
Treatment Period
Participant flow — Treatment Period
MilestoneRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Started007674747471727273
Treated with bi 690517 or placebo matching bi 690517007673747470717273
Completed006350555861544866
Not completed00132419161018247
Withdrew: Reason missing0010000000
Withdrew: Other but not sponsor termination0086675872
Withdrew: Protocol deviation0000000010
Withdrew: No reason available0001020100
Withdrew: Burden of study procedures0000100000
Withdrew: Change of residence0000010000
Withdrew: Adverse event0041612648165
Withdrew: Not treated with study drug0001001100

Outcome measures

PrimaryChange From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients

The adjusted mean change (95% confidence interval) in log transformed FMV UACR from baseline at 14 weeks is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Least squares mean · log (milligram/gram)
Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients
log (milligram/gram)3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
Change From Treatment Period Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in First Morning Void (FMV) Urine After 14 Weeks - All Patients-0.235 (-0.355 to -0.114)-0.553 (-0.681 to -0.425)-0.487 (-0.616 to -0.357)-0.066 (-0.184 to 0.051)
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · MMRM · p = 0.0499 · Mean difference (net): -0.168 · 95% CI -0.337 to -0.000Least Squares Mean of "3 mg BI 690517" - Least Squares Mean of "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · MMRM · p = <.0001 · Mean difference (net): -0.486 · 95% CI -0.660 to -0.313Least Squares Mean of "10 mg BI 690517" - Least Squares Mean of "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · MMRM · p = <.0001 · Mean difference (net): -0.421 · 95% CI -0.596 to -0.246Least Squares Mean of "20 mg BI 690517" - Least Squares Mean of "Placebo to BI 690517".
  • 3 mg BI 690517 vs 10 mg BI 690517 vs 20 mg BI 690517 vs Placebo to BI 690517 · MCPMod Emax model fit · p = 0.0000 (P-value was rounded to four decimal places.)Emax model fit assumption: 80% of the maximum effect is achieved at 10 mg.
  • 3 mg BI 690517 vs 10 mg BI 690517 vs 20 mg BI 690517 vs Placebo to BI 690517 · MCPMod linear model fit · p = 0.0000 (P-value was rounded to four decimal places.)Linear model fit assumption: No assumption is needed.
  • 3 mg BI 690517 vs 10 mg BI 690517 vs 20 mg BI 690517 vs Placebo to BI 690517 · MCPMod exponential model fit · p = 0.0003Exponential model fit assumption: 15% of the maximum effect is achieved at 10 mg.
PrimaryPercent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients

Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for all patients is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Median · percent change of FMV UACR
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients
percent change of FMV UACR3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - All Patients-20.9 (-29.9 to -10.8)-42.5 (-49.4 to -34.6)-38.5 (-46.0 to -30.0)-6.4 (-16.8 to 5.3)
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Median difference (net): -15.5 · 95% CI -28.6 to -0.0Median of "3 mg BI 690517" - Median of "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Median difference (net): -38.5 · 95% CI -48.3 to -26.8Median of "10 mg BI 690517" - Median of "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Median difference (net): -34.3 · 95% CI -44.9 to -21.8Median of "20 mg BI 690517" - Median of "Placebo to BI 690517".
PrimaryChange From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin

The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Least squares mean · log (milligram/gram)
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin
log (milligram/gram)Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Placebo Matching Empagliflozin-0.254 (-0.441 to -0.068)-0.496 (-0.693 to -0.299)-0.455 (-0.666 to -0.245)-0.027 (-0.208 to 0.155)
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · MMRM · p = 0.0867 · Mean difference (net): -0.227 · 95% CI -0.488 to 0.033Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" - Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · MMRM · p = 0.0007 · Mean difference (net): -0.469 · 95% CI -0.737 to -0.201Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" - Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · MMRM · p = 0.0027 · Mean difference (net): -0.429 · 95% CI -0.707 to -0.151Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 6905177" - Least Squares Mean of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
PrimaryPercent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin

Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of placebo matching empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Median · percent change of FMV UACR
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin
percent change of FMV UACRTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) Back Transformed From MMRM Estimate - Patients With Background Therapy of Placebo Matching Empagliflozin-22.4 (-35.6 to -6.5)-39.1 (-50.0 to -25.8)-36.6 (-48.6 to -21.7)-2.6 (-18.8 to 16.8)
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Median difference (net): -20.3 · 95% CI -38.6 to 3.4Median of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" - median of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Median difference (net): -37.4 · 95% CI -52.2 to -18.2Median of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" - median of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517"
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Median difference (net): -34.9 · 95% CI -50.7 to -14.0Median of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 6905177" - median of "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
PrimaryChange From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin

The adjusted mean change (95% confidence interval) in log transformed first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline at 14 weeks for patients with background therapy of empagliflozin in the Run-in period is presented. The adjusted means and 95 % confidence intervals were estimated by restricted maximum likelihood-based mixed models for repeated measures ((REML)-based MMRM) which includes the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Least squares mean · log (milligram/gram)
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin
log (milligram/gram)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
Change From Baseline to Week 14 in the Log Transformed FMV UACR - Patients With Background Therapy of Empagliflozin-0.210 (-0.366 to -0.055)-0.614 (-0.783 to -0.445)-0.516 (-0.675 to -0.357)-0.112 (-0.264 to 0.040)
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · MMRM · p = 0.3737 · Mean difference (net): -0.098 · 95% CI -0.316 to 0.119Least Squares Mean of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" - Least Squares Mean of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · MMRM · p = <.0001 · Mean difference (net): -0.502 · 95% CI -0.730 to -0.275Least Squares Mean of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" - Least Squares Mean of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · MMRM · p = 0.0004 · Mean difference (net): -0.404 · 95% CI -0.625 to -0.184Least Squares Mean of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" - Least Squares Mean of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
PrimaryPercent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin

Percent change of first morning void (FMV) urine albumine creatinine ratio (UACR) from baseline to Week 14 based on adjusted median (95% confidence interval (CI)) back transformed from mixed models for repeated measures (MMRM) estimate for patients with background therapy of empagliflozin in the Run-in period is presented. Percent change of FMV UACR= (FMV UACR at Week 14-FMV UACR at baseline)\*100/(FMV UACR at baseline). MMRM included the fixed effects of treatment at each visit, baseline (continuous) at each visit, and baseline, visit, treatment, background medication (empagliflozin or placebo matching empagliflozin) and randomisation stratum as main effects, as well as random effects of patient.

Time frame:
The MMRM model is a longitudinal analysis and it incorporated UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period.
Reported as:
Median · percent change of FMV UACR
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin
percent change of FMV UACRTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
Percent Change of FMV UACR From Baseline to Week 14 Based on Adjusted Median (95% CI) of MMRM Estimate - Patients With Background Therapy of Empagliflozin-19.0 (-30.6 to -5.4)-45.9 (-54.3 to -35.9)-40.3 (-49.1 to -30.0)-10.6 (-23.2 to 4.1)
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Median difference (net): -9.4 · 95% CI -27.1 to 12.7Median of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" - median of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Median difference (net): -39.5 · 95% CI -51.8 to -24.0Median of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" - median of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Median difference (net): -33.2 · 95% CI -46.5 to -16.8Median of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" - median of "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation

Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Multiple Imputation40736624
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0136 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.08 · 95% CI 1.16 to 3.72Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 7.02 · 95% CI 3.94 to 12.49Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.48 · 95% CI 3.09 to 9.71Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder

Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder40625723
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0111 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.15 · 95% CI 1.19 to 3.88Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.33 · 95% CI 3.49 to 11.49Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.21 · 95% CI 2.88 to 9.44Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)

Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)
ParticipantsBI 690517 3 mg10 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Week - All Patients - Last Observation on Treatment Carried Forward (LOCF)45677331
Statistical analysis
  • BI 690517 3 mg vs Placebo to BI 690517 · Regression, Logistic · p = 0.0348 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.80 · 95% CI 1.04 to 3.09Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.12 · 95% CI 2.40 to 7.08Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.02 · 95% CI 2.91 to 8.67Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis

Number of patients with UACR response I is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis40625723
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0111 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.15 · 95% CI 1.19 to 3.88Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.33 · 95% CI 3.49 to 11.49Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.21 · 95% CI 2.88 to 9.44Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation

Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation19313010
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0419 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.44 · 95% CI 1.03 to 5.74Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.09 · 95% CI 2.64 to 14.08Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.13 · 95% CI 2.64 to 14.25Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder

Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder1928259
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0195 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.88 · 95% CI 1.19 to 7.02Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.38 · 95% CI 2.65 to 15.35Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.39 · 95% CI 2.60 to 15.67Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)

Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)22313214
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0767 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.03 · 95% CI 0.93 to 4.42Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0003 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.11 · 95% CI 1.89 to 8.91Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.69 · 95% CI 2.15 to 10.24Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis

Number of patients with UACR response I for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis1928259
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0195 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.88 · 95% CI 1.19 to 7.02Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.38 · 95% CI 2.65 to 15.35Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.39 · 95% CI 2.60 to 15.67Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation

Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation21423614
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.1398 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.82 · 95% CI 0.82 to 4.04Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 8.42 · 95% CI 3.73 to 19.02Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 · Odds ratio (or): 4.98 · 95% CI 2.28 to 10.90Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder

Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder21343214
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.1884 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.71 · 95% CI 0.77 to 3.79Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.80 · 95% CI 2.94 to 15.72Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0003 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.46 · 95% CI 2.00 to 9.94Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward

Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward23364117
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.2140 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.62 · 95% CI 0.76 to 3.46Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0003 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.13 · 95% CI 1.93 to 8.85Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.43 · 95% CI 2.52 to 11.71Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis

Number of patients with UACR response I for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response I was defined as decrease of at least 30% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response I, Defined as Decrease of at Least 30% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis21343214
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.1884 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.71 · 95% CI 0.77 to 3.79Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.80 · 95% CI 2.94 to 15.72Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0003 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.46 · 95% CI 2.00 to 9.94Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation

Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 week. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients -Multiple Imputation68828146
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0024 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.18 · 95% CI 1.32 to 3.61Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.05 · 95% CI 2.39 to 6.86Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.87 · 95% CI 2.29 to 6.55Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder

Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Missing as Non-Responder67717044
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0019 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.26 · 95% CI 1.35 to 3.77Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.81 · 95% CI 2.20 to 6.59Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.67 · 95% CI 2.12 to 6.35Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)

Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Last Observation on Treatment Carried Forward (LOCF)67878553
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0418 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.67 · 95% CI 1.02 to 2.74Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.91 · 95% CI 2.30 to 6.65Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.58 · 95% CI 2.11 to 6.05Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis

Number of patients with UACR response II is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis
Participants3 mg BI 69051710 mg BI 69051720 mg BI 690517Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - All Patients - Complete Case Analysis67717044
Statistical analysis
  • 3 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0019 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.26 · 95% CI 1.35 to 3.77Odds ratio of "3 mg BI 690517" vs. "Placebo to BI 690517".
  • 10 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.81 · 95% CI 2.20 to 6.59Odds ratio of "10 mg BI 690517" vs. "Placebo to BI 690517".
  • 20 mg BI 690517 vs Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.67 · 95% CI 2.12 to 6.35Odds ratio of "20 mg BI 690517" vs. "Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation

Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Multiple Imputation33353922
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0285 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.20 · 95% CI 1.09 to 4.45Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0038 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.90 · 95% CI 1.41 to 5.96Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0002 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.15 · 95% CI 1.97 to 8.72Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder

Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Placebo Matching Empagliflozin - Missing as Non-Responder32323220
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0116 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.56 · 95% CI 1.23 to 5.31Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0032 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.08 · 95% CI 1.46 to 6.52Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0004 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.07 · 95% CI 1.86 to 8.91Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)

Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void (FMV) urine of UACR from treatment period baseline to 14 weeks. LOCF uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in FMV Urine of UACR From Treatment Period Baseline to 14 Weeks - Background Therapy of Placebo Matching Empagliflozin - Last Observation on Treatment Carried Forward (LOCF)28414125
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.4092 (P-value was rounded to four decimal places.) · Odds ratio (or): 1.34 · 95% CI 0.67 to 2.69Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0005 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.66 · 95% CI 1.77 to 7.58Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0002 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.04 · 95% CI 1.92 to 8.49Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation

Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The multiple imputation filled in missing values at Week 14 based on other data observed in the same patient using regression.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the multiple imputation approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Multiple Imputation35474224
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0348 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.16 · 95% CI 1.06 to 4.43Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0000 (P-value was rounded to four decimal places.) · Odds ratio (or): 6.08 · 95% CI 2.73 to 13.57Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0007 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.58 · 95% CI 1.71 to 7.52Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder

Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. The missing as non-responder imputes patients with missing Week 14 data as non-responders.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Missing as Non-Responder35393824
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0578 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.01 · 95% CI 0.98 to 4.14Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.12 · 95% CI 2.23 to 11.78Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0022 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.32 · 95% CI 1.54 to 7.16Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward

Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Last observation on treatment carried forward (LOCF) uses the last value observed on treatment to substitute all missing values until Week 14.

Time frame:
UACR measurements from baseline (Week 6,7 or 8 of the Run-in period) and Week 6, Week 10 and Week 12-14 of Treatment period were used for the last observation carried forward approach.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Last Observation on Treatment Carried Forward39464428
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0342 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.17 · 95% CI 1.06 to 4.44Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0003 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.23 · 95% CI 1.93 to 9.24Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0023 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.19 · 95% CI 1.52 to 6.73Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis

Number of patients with UACR response II for patients with background therapy of placebo matching empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis
ParticipantsTreatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks -Patients With Background Therapy of Placebo Matching Empagliflozin - Complete Case Analysis32323220
Statistical analysis
  • Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0116 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.56 · 95% CI 1.23 to 5.31Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 3 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0032 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.08 · 95% CI 1.46 to 6.52Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 10 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
  • Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517 vs Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517 · Regression, Logistic · p = 0.0004 (P-value was rounded to four decimal places.) · Odds ratio (or): 4.07 · 95% CI 1.86 to 8.91Odds ratio of "Treatment period: Placebo to empagliflozin 10 mg + 20 mg BI 690517" vs. "Treatment period: Placebo to empagliflozin 10 mg + Placebo to BI 690517".
SecondaryUACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis

Number of patients with UACR response II for patients with background therapy of empagliflozin in the Run-in period is reported. UACR response II was defined as decrease of at least 15% absolute change in First Morning Void urine of UACR from treatment period baseline to 14 weeks. Complete case analysis used patients with both baseline and Week 14 data available.

Time frame:
At baseline (Week 6,7 or 8 of the Run-in period) and at Week 12-14 of the Treatment Period.
Reported as:
Count of participants · Participants
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis
ParticipantsTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517
UACR Response II, Defined as Decrease of at Least 15% Absolute Change in First Morning Void Urine of UACR From Treatment Period Baseline to 14 Weeks - Patients With Background Therapy of Empagliflozin - Complete Case Analysis35393824
Statistical analysis
  • Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0578 (P-value was rounded to four decimal places.) · Odds ratio (or): 2.01 · 95% CI 0.98 to 4.14Odds ratio of "Treatment period: 10 mg empagliflozin + 3 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0001 (P-value was rounded to four decimal places.) · Odds ratio (or): 5.12 · 95% CI 2.23 to 11.78Odds ratio of "Treatment period: 10 mg empagliflozin + 10 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".
  • Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517 vs Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517 · Regression, Logistic · p = 0.0022 (P-value was rounded to four decimal places.) · Odds ratio (or): 3.32 · 95% CI 1.54 to 7.16Odds ratio of "Treatment period: 10 mg empagliflozin + 20 mg BI 690517" vs. "Treatment period: 10 mg empagliflozin + Placebo to BI 690517".

Adverse events

Collected over Run-in period: From first study drug administration in the run-in period until end of the residual effect period (REP) (i.e., 7 days), up to 9 weeks. Treatment period: From first study drug administration in the treatment period until end of REP (i.e. 7 days), up to 15 weeks. All-Cause Mortality for treatment period: From study drug administration in the treatment period until end of the follow-up period, up to 18 weeks. Continues in the description.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Period: 10 mg Empagliflozin0/356 (0%)9/356 (2.5%)17/356 (4.8%)
Run-in Period: Placebo to Empagliflozin 10 mg2/357 (0.6%)20/357 (5.6%)15/357 (4.2%)
Treatment Period: 10 mg Empagliflozin + 3 mg BI 6905171/76 (1.3%)4/76 (5.3%)11/76 (14.5%)
Treatment Period: 10 mg Empagliflozin + 10 mg BI 6905171/73 (1.4%)7/73 (9.6%)20/73 (27.4%)
Treatment Period: 10 mg Empagliflozin + 20 mg BI 6905170/74 (0%)5/74 (6.8%)19/74 (25.7%)
Treatment Period: 10 mg Empagliflozin + Placebo to BI 6905172/74 (2.7%)7/74 (9.5%)13/74 (17.6%)
Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 6905170/70 (0%)3/70 (4.3%)15/70 (21.4%)
Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 6905171/71 (1.4%)4/71 (5.6%)16/71 (22.5%)
Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 6905171/72 (1.4%)6/72 (8.3%)25/72 (34.7%)
Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 6905170/73 (0%)3/73 (4.1%)9/73 (12.3%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
Adrenal insufficiencyEndocrine disorders1/3560/3570/762/731/741/741/700/712/720/73
Acute kidney injuryRenal and urinary disorders1/3562/3570/761/730/740/740/701/712/721/73
Cardiac failure congestiveCardiac disorders0/3560/3570/760/730/740/741/700/710/720/73
Subcapsular renal haematomaRenal and urinary disorders0/3560/3570/760/730/740/741/700/710/720/73
Sudden deathGeneral disorders0/3560/3570/760/730/741/740/701/710/720/73
Dengue feverInfections and infestations0/3560/3570/760/730/740/740/701/710/720/73
PneumoniaInfections and infestations1/3561/3571/761/730/741/740/701/710/721/73
SepsisInfections and infestations0/3561/3570/760/730/740/740/701/710/720/73
Ischaemic cerebral infarctionNervous system disorders0/3560/3570/760/730/740/740/701/710/720/73
Intracardiac thrombusCardiac disorders0/3560/3570/760/730/740/740/700/711/720/73
Most frequent other events
Most frequent other events
EventRun-in Period: 10 mg EmpagliflozinRun-in Period: Placebo to Empagliflozin 10 mgTreatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517
HyperkalaemiaMetabolism and nutrition disorders8/3568/3575/7611/737/745/748/707/7117/724/73
Glomerular filtration rate decreasedInvestigations4/3561/3574/768/737/742/741/707/716/723/73
Cortisol decreasedInvestigations0/3561/3572/761/730/741/743/704/712/720/73
HypotensionVascular disorders2/3560/3570/764/732/741/741/700/710/720/73
Upper respiratory tract infectionInfections and infestations4/3565/3571/761/734/744/742/701/713/722/73

Baseline characteristics

Randomised Set (RS): This patient set included all entered and randomised patients based on the treatment groups they were randomised to at the randomisation prior to the treatment period (i.e. at second randomisation (R2)), regardless of being treated by BI 690517 or not.

Age, Continuous
Age, Continuous(Years)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517Total
Mean65.4 ± 11.264.4 ± 12.361.8 ± 12.263.4 ± 10.364.4 ± 11.864.8 ± 9.964.3 ± 10.762.3 ± 11.463.8 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517Total
Female2730203120232718196
Male4944544351494555390
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517Total
Hispanic or Latino2521122022211824163
Not Hispanic or Latino5153625449515449423
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517Total
American Indian or Alaska Native0212223113
Asian1727201923151916156
Native Hawaiian or Other Pacific Islander000000011
Black or African American967103991063
White4935454242454044342
More than one race1411111111
Unknown or Not Reported000000000
Urine Albumin Creatinine Ratio (UACR) at baseline
Urine Albumin Creatinine Ratio (UACR) at baseline(milligram/gram)Treatment Period: 10 mg Empagliflozin + 3 mg BI 690517Treatment Period: 10 mg Empagliflozin + 10 mg BI 690517Treatment Period: 10 mg Empagliflozin + 20 mg BI 690517Treatment Period: 10 mg Empagliflozin + Placebo to BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 3 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 10 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + 20 mg BI 690517Treatment Period: Placebo to Empagliflozin 10 mg + Placebo to BI 690517Total
Mean780.3 ± 828.8740.8 ± 915.0695.4 ± 748.0801.4 ± 1132.3934.0 ± 1363.6646.2 ± 685.2785.0 ± 885.7684.4 ± 715.1757.9 ± 930.5
08

Study locations

203 sites
  • Aventiv Research Inc.
    Mesa, Arizona 85206, United States
  • AKDHC Medical Research Services, LLC
    Phoenix, Arizona 85027, United States
  • Clearview Medical Research, LLC
    Canyon Country, California 91351, United States
  • Pacific Renal Associates
    Long Beach, California 90806, United States
  • Amicis Research Center
    Northridge, California 91324, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • California Kidney Specialists
    San Dimas, California 91773, United States
  • Colorado Kidney Care
    Denver, Colorado 80230, United States
  • Clinical Research of Brandon LLC
    Brandon, Florida 33511, United States
  • Horizon Research Group
    Coral Gables, Florida 33134, United States
  • Elixia Fort Lauderdale, LLC
    Fort Lauderdale, Florida 33308, United States
  • South Florida Research Institute
    Lauderdale Lakes, Florida 33313, United States
  • San Marcus Research Clinic, Inc.
    Miami, Florida 33014, United States
  • Total Research Group, LLC
    Miami, Florida 33126, United States
  • Horizon Research Group, LLC
    Miami, Florida 33150, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • Pines Care Research Center
    Pembroke Pines, Florida 33024, United States
  • Elixia Tampa, LLC
    Temple Terrace, Florida 33637, United States
  • Boise Kidney and Hypertension PLLC
    Nampa, Idaho 83687, United States
  • Cedar Crosse Research Center
    Chicago, Illinois 60607, United States
  • Kansas Nephrology Research Institute, LLC
    Wichita, Kansas 67214, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Elite Research Center, LLC
    Flint, Michigan 48532, United States
  • Clinical Research Consultants, LLC
    Kansas City, Missouri 64111, United States
  • Forte Family Practice
    Las Vegas, Nevada 89103, United States
  • New Mexico Clinical Research and Osteoporosis Center, Inc.
    Albuquerque, New Mexico 87106, United States
  • Triad Internal Medicine
    Asheboro, North Carolina 27203, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Diabetes & Endocrinology Associates of Stark County
    Canton, Ohio 44718, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Heritage Valley Medical Group
    Beaver, Pennsylvania 15009, United States
  • Elixia Upland, LLC
    Upland, Pennsylvania 19013, United States
  • Monument Health
    Rapid City, South Dakota 57701, United States
  • Knoxville Kidney Center PLLC
    Knoxville, Tennessee 37923, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • Academy Of Diabetes, Thyroid And Endocrine, PA
    El Paso, Texas 79935, United States
  • PrimeCare Medical Group
    Houston, Texas 77024, United States
  • P&I Clinical Research, LLC
    Lufkin, Texas 75904, United States
  • Simcare Medical Research, LLC
    Sugar Land, Texas 77478, United States
  • Providence Medical Research Center
    Spokane, Washington 99204, United States
  • Universal Research Group, LLC
    Tacoma, Washington 98405, United States
  • CIMEL centro de Investigaciones Médicas Lanús
    Buenos Aires, B1824KAJ, Argentina
  • CEDIC - Centro de Investigacion Clinica
    Caba, C1060ABN, Argentina
  • Glenny Corp. S.A. Bioclinica Argentina
    Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
  • Instituto Privado de Investigaciones Clínica Córdoba S.A.
    Cordoba, X5000AAW, Argentina
  • Centro de Salud Renal Junín
    Junín, B6000GMA, Argentina
  • Centro de Investigaciones Médicas Mar del Plata
    Mar del Plata, B7600FYK, Argentina
  • Instituto Médico Catamarca - IMEC
    Rosario, S2000AJU, Argentina
  • CEMEDIC - Centro de Especialidades Medicas
    Villa Luro, C1440CFD, Argentina
  • John Hunter Hospital
    New Lambton Heights, New South Wales 2305, Australia
  • Monash University
    Box Hill, Victoria 3128, Australia
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Brussels - UNIV UZ Brussel
    Brussel, 1090, Belgium
  • Brussels - UNIV Saint-Luc
    Bruxelles, 1200, Belgium
  • La Louvière - UNIV CHU Tivoli
    La Louvière, 7100, Belgium
  • UZ Leuven
    Leuven/Vlaams-Brabant, 3000, Belgium
  • Charleroi - UNIV CHU de Charleroi
    Lodelinsart, 6042, Belgium
  • Hospital Universitário João de Barros Barreto
    Belém, CEP 66073-, Brazil
  • Faculdade de Medicina de Botucatu - UNESP
    Botucatu, 18618-687, Brazil
  • Fundação Pró Renal Brasil
    Curitiba, 80440-020, Brazil
  • Universidade Federal do Rio Grande do Sul
    Porto Alegre, 90430-001, Brazil
  • Ruschel Medicina e Pesquisa Clínica
    Rio de Janeiro, 22270-060, Brazil
  • BR Trials
    Sao Paulo, 01236-030, Brazil
  • Centro de Pesquisa Clinica - CPCLIN
    Sao Paulo, 01244-030, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    São Bernardo do Campo, 09780-000, Brazil
  • Hospital do RIM - UNIFESP
    São Paulo, 04023-062, Brazil
  • Medical Center Rusemed
    Ruse, 7013, Bulgaria
  • Robert Koch Clinic Sofia
    Sofia, 1407, Bulgaria
  • Medical Center Synexus Sofia EOOD
    Sofia, 1784, Bulgaria
  • MHAT Prof Stoyan Kirkovich AD
    Stara Zagora, 6000, Bulgaria
  • The Bailey Clinic
    Red Deer, Alberta T4N 6V7, Canada
  • LMC Clinical Research Inc. (Brampton)
    Brampton, Ontario L6S 0C6, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
  • Sameh Fikry Medicine Professional Corporation
    Waterloo, Ontario N2J 1C4, Canada
  • Shivinder Jolly, Nephrologist
    Waterloo, Ontario N2T 0C1, Canada
  • Recherche GCP Research
    Montreal, Quebec H1M 1B1, Canada
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • The First Afiliated Hospital, Sun Yet-sen University
    Guangzhou, 510080, China
  • Zhejiang Province People's Hospital
    Hangzhou, 310014, China
  • The First People's Hospital of Nanning
    Nanning, 530000, China
  • Huashan Hospital, Fudan University
    Shanghai, 200040, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • DIKa centrum s.r.o.
    Havirov, 73601, Czechia
  • Synexus Czech s.r.o.
    Prague, 120 00, Czechia
  • MILAN KVAPIL s.r.o.
    Pribram, 26101, Czechia
  • Hospital Slany, Internal Department
    Slany, 274 01, Czechia
  • Satucon Oy
    Kuopio, 70100, Finland
  • Tampere University Hospital
    Tampere, 33521, Finland
  • Turku University Hospital / TYKS
    Turku, 20520, Finland
  • Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen
    Bad Oeynhausen, 32545, Germany
  • Institut für klinische Forschung und Entwicklung (IKFE) Berlin GmbH
    Berlin, 10437, Germany
  • Cardiologicum Dresden und Pirna
    Dresden, 01277, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • DaVita Clinical Research Germany GmbH
    Düsseldorf, 40210, Germany
  • Synexus Clinical Research GmbH
    Frankfurt, 60313, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Synexus Clinical Research GmbH
    Leipzig, 04103, Germany
  • Universitätsklinikum Würzburg AÖR
    Würzburg, 97080, Germany
  • General Hospital of Athens "Laiko"
    Athens, 115 27, Greece
  • "Attiko" Hospital of Athens
    Athens, 124 62, Greece

Showing the first 100 of 203 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the time frame criteria given under number 4 are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jun 2023, 17 months.

Results were first posted in Aug 2024, 1 year 2 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 17 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 10, 2022
StartActual
Jan 11, 2022
Primary completionActual
Jun 19, 2023
CompletionActual
Jul 10, 2023
Results first posted
Aug 29, 2024
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05182840
Responsible party
Sponsor
First posted
Jan 10, 2022
Start date
Jan 11, 2022
Primary completion
Jun 19, 2023
Completion
Jul 10, 2023
Results posted
Aug 29, 2024
Last update
Oct 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vicadrostat · Empagliflozin

Start the discussion